卖什么
AI Diagnosis of Heart Disease
商业模式拆解
买家：谁掌握预算？
Health system leaders: cardiovascular service line directors, imaging and IT/security procurement.
触发点：什么让他们现在购买？
Undiagnosed cardiac amyloid and new reimbursement: CPT 0932T outpatient (~$313 national average) and Medicare NTAP up to $2,275 per inpatient stay effective Oct 1 2026.
工作流：什么输入变成什么输出？
Standard DICOM studies go in (on-premise VM or validated cloud), AI result returns into the study the cardiologist reads; go-live in about four weeks.
经济账：省了什么，怎么收费？
未核实Hospital is reimbursed separately for the AI analysis (CPT 0932T, NTAP), which funds the software license.
渠道：怎么接触到客户？
Direct enterprise sales to health systems (Request a Demo / scoping call).
融资历史与报道
| 融资日期 | 轮次 | 金额 | 投资方 | 来源 |
|---|---|---|---|---|
| — | YC 2022 夏季 | — | Y Combinator | ycombinator.com |
档案汇总自公开报道和公司官网。商业模式部分是 MaxBC 对这些材料的解读，不是已确认的事实；未知之处留空，不作猜测。 更新于 2026-10-12.